$28.27
2.28%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US04272N1028
Symbol
AVBP

Arrivent Biopharma Inc Stock price

$28.27
-2.24 7.34% 1M
+3.38 13.58% 6M
+8.15 40.51% YTD
+9.44 50.13% 1Y
+10.27 57.06% 3Y
+10.27 57.06% 5Y
+10.27 57.06% 10Y
+10.27 57.06% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.66 2.28%
ISIN
US04272N1028
Symbol
AVBP
Industry

Is Arrivent Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.0b
Net debt
positive
Cash
$373.1m
Shares outstanding
48.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
3.8
Financial Health
Equity Ratio
92.2%
Return on Equity
-54.1%
ROCE
-48.0%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$19.1m | -
SBC as % of FCF
-
SBC Growth 1Y
158.0%
Share Count Growth 1Y
28.9%
Shareholder Yield
-28.9%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-175.9m
Net Income
$-163.7m
Free Cash Flow | ex SBC
$-147.9m | $-167.0m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-18.6%
Net Income
-19.5%
Free Cash Flow
-16.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-3.4
FCF per Share
$-3.1
Short interest
18.9%
Employees
77
Rev per Employee
$0.0

Arrivent Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Arrivent Biopharma Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Arrivent Biopharma Inc forecast:

Buy
94%
Hold
6%

Financial data from Arrivent Biopharma Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
66% 66%
-
- Research and Development Expense 144 144
12% 12%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -176 -176
19% 19%
-
Net Profit -164 -164
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Arrivent Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrivent Biopharma Inc Stock News

Neutral
GlobeNewsWire
●
about 2 months ago
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.

Company Profile

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.

Head office United States
CEO Dr. Yao
Employees 77
Website arrivent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today